In this episode, host Henry Norton sits down with Gautam Kainth, Partner at TCP Health Ventures, to unpack why medtech investing fundamentally differs from traditional tech and what founders need to know about positioning their companies for strategic exits.

Gautam brings over 20 years of investment experience with $1+ billion in deployed capital across 30+ transactions spanning the US, Europe, Asia, and Africa. He leads TCP's medtech investments and currently serves on the boards of Tioga Cardiovascular, Adona Medical, and Plexaa, with active oversight of a 12-company portfolio.

He shares TCP's playbook for deploying over $220 million across three funds, the AI-hardware integration reshaping devices, and the tactical framework for making your startup attractive to the right acquirers including why commercial infrastructure fit matters more than most founders realize.

Key Topics:

• Why medtech allows multiple winners unlike Big Tech monopolies (the COVID vaccine thesis)

• TCP's fund strategy: $7 billion AUM platform with 27 years in venture

• Series A focus with $5-15M check sizes and board-level involvement

• The convergence of AI models with hardware devices across cardiovascular, imaging, and diagnostics

• Strategic vs ancillary product positioning for M&A conversations

• The Shifamed-style build-to-buy model that creates plug-and-play acquisition opportunities

Related Insights:

• How Gautam's financial services background (JP Morgan, EY transaction advisory) translates to medtech's regulatory complexity

• Why TCP exited three companies and actively manages 12 with board seats on nine

• Commercial infrastructure fit as the first filter before pitching strategics

• Mini manufacturing facilities that enable pilot commercialization post-acquisition

• The importance of regulatory champions and clinical programs housed within startups

• TCP's Northgate Capital sister company managing $5B in tech and venture investments

Core Challenges:

• Founders waste time pitching strategics without commercial infrastructure alignment. If your cardiovascular device doesn't fit their existing sales team, you're pitching the wrong acquirer. Match your product to their distribution machinery first.

• Strategic vs ancillary positioning determines your exit path. If you're strategic to them, explore M&A immediately. If you're ancillary, pursue their venture arm for a minority investment, prove performance over time, then revisit acquisition conversations years later.

• Building for acquisition requires plug-and-play infrastructure. Companies need in-house regulatory teams, clinical trial execution capabilities, and pilot manufacturing facilities to enable seamless post-acquisition commercialization—this is what separates TCP's portfolio from competitors.

🎧 Tune in now to learn how a Partner managing $220M+ in medtech capital evaluates deals and what makes your company acquisition-ready.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠